[
  {
    "ALL": "Acute Lymphoblastic Leukemia"
  },
  {
    "API": "Active Pharmaceutical Ingredient"
  },
  {
    "Ara-C": "cytarabine"
  },
  {
    "CMO": "Contract Manufacturing Organization"
  },
  {
    "CNS": "Central Nervous System"
  },
  {
    "CR": "complete remission"
  },
  {
    "DFS": "disease-free survival"
  },
  {
    "DNR": "daunorubicine"
  },
  {
    "DEX": "dexamethasone"
  },
  {
    "EFS": "event-free survival"
  },
  {
    "EIG": "événement indésirable grave (see SAE)"
  },
  {
    "G/L": "Giga /liter"
  },
  {
    "GMP": "Good Manufacturing Practices"
  },
  {
    "HD-MTX": "High-Dose Methotrexate"
  },
  {
    "HR": "High Risk"
  },
  {
    "HSCT": "Hematopoietic Stem Cell Transplantation"
  },
  {
    "IM": "intramuscular"
  },
  {
    "IMP": "Investigational Medicinal Product"
  },
  {
    "IT": "intrathecal injection"
  },
  {
    "IV": "intravenous infusion"
  },
  {
    "MR": "Medium Risk"
  },
  {
    "MRD": "minimal residual disease"
  },
  {
    "MTX": "methotrexate"
  },
  {
    "NCI": "National Cancer Institute"
  },
  {
    "NCI-CTCAE": "National Cancer Institute Common Terminology Criteria for Adverse Events"
  },
  {
    "OS": "overall survival"
  },
  {
    "PEG": "pegaspargase i.e. pegylated asparaginase"
  },
  {
    "PNN": "neutrophils"
  },
  {
    "PRED": "prednisone"
  },
  {
    "SAE": "severe adverse event"
  },
  {
    "6-MP": "6-mercaptopurine"
  },
  {
    "SR": "Standard Risk"
  },
  {
    "6-TG": "6-thioguanine"
  },
  {
    "TP": "Time Point"
  },
  {
    "TLP": "Traumatic Lumbar Punction"
  },
  {
    "VCR": "vincristine"
  },
  {
    "VHR": "Very High Risk"
  },
  {
    "WBC": "White Blood Cell Count"
  }
]